SoFi CEO enters prepaid forward contract on 1.5 million shares
H.C. Wainwright maintained its buy rating and $75.00 price target on Silence Therapeutics (NASDAQ:SLN), representing significant upside potential from the current price of $5.59, following the company’s presentation of updated clinical data at the European Hematology Association Congress in Milan, Italy. InvestingPro analysis suggests the stock is slightly undervalued, with strong returns over the past three months.
On Wednesday, Silence presented new results from the Phase 1 portion of its SANRECO program evaluating divesiran, a small interfering RNA therapeutic, in patients with polycythemia vera, a chronic hematologic disorder with limited long-term treatment options.
The data showed divesiran was well tolerated across all dose levels and demonstrated sustained reductions in hematocrit and hemoglobin levels. The treatment eliminated the need for phlebotomy in well-controlled patients and confirmed target engagement through sustained hepcidin induction and iron redistribution.
H.C. Wainwright noted the results further validate divesiran’s profile as a potential first-in-class RNAi therapeutic for polycythemia vera and represent a critical de-risking milestone that supports the commercial and clinical potential of both divesiran and Silence’s broader RNAi platform.
Enrollment continues in the randomized Phase 2 portion of the SANRECO trial with full enrollment expected by year-end 2025, suggesting potential data availability in the fourth quarter of 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.